ArticlePloS one2012
Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.International journal of molecular sciences · 2021Review
- Myelin Basic Protein and Cardiac Sympathetic Neurodegeneration in Nonhuman Primates.Neurology research international · 2021Article
- Adrenergic supersensitivity and impaired neural control of cardiac electrophysiology following regional cardiac sympathetic nerve loss.Scientific reports · 2020Article
- Effects of Cardiac Sympathetic Neurodegeneration and PPARBioMed research international · 2020Article
- Article
- Autonomic dysfunction in Parkinson disease and animal models.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019Review
- In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration.NPJ Parkinson's disease · 2018Article
- Nonhuman Primate Models of Neurodegenerative Disorders.ILAR journal · 2017Article
- Non-motor features of Parkinson disease.Nature reviews. Neuroscience · 2017Review
- Neurotoxin-Induced Catecholaminergic Loss in the Colonic Myenteric Plexus of Rhesus Monkeys.Journal of Alzheimer's disease & Parkinsonism · 2016Article
- α-Synuclein and nonhuman primate models of Parkinson's disease.Journal of neuroscience methods · 2015Review
- IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques.Molecular imaging and biology · 2015Article
- Cardiac Dysregulation and Myocardial Injury in a 6-Hydroxydopamine-Induced Rat Model of Sympathetic Denervation.PloS one · 2015Article
- Recent progress of imaging agents for Parkinson's disease.Current neuropharmacology · 2014Article
- Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.American journal of nuclear medicine and molecular imaging · 2014Review
- Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculature.Journal of inflammation research · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease presents nonmotor complications such as autonomic dysfunction that do not respond to traditional anti-parkinsonian therapies. The lack of established preclinical monkey models of Parkinson's disease with cardiac dysfunction hampers development and testing of new treatments to alleviate or prevent this feature. This study aimed to assess the feasibility of developing a model of cardiac dysautonomia in nonhuman primates and preclinical evaluations tools. Five rhesus monkeys received intravenous injections of 6-hydroxydopamine (total dose: 50 mg/kg). The animals were evaluated before and after with a battery of tests, including positron emission tomography with the norepinephrine analog (11)C-meta-hydroxyephedrine. Imaging 1 week after neurotoxin treatment revealed nearly complete loss of specific radioligand uptake. Partial progressive recovery of cardiac uptake found between 1 and 10 weeks remained stable between 10 and 14 weeks. In all five animals, examination of the pattern of uptake (using Logan plot analysis to create distribution volume maps) revealed a persistent region-specific significant loss in the inferior wall of the left ventricle at 10 (P<0.001) and 14 weeks (P<0.01) relative to the anterior wall. Blood levels of dopamine, norepinephrine (P<0.05), epinephrine, and 3,4-dihydroxyphenylacetic acid (P<0.01) were notably decreased after 6-hydroxydopamine at all time points. These results demonstrate that systemic injection of 6-hydroxydopamine in nonhuman primates creates a nonuniform but reproducible pattern of cardiac denervation as well as a persistent loss of circulating catecholamines, supporting the use of this method to further develop a monkey model of cardiac dysautonomia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.